DDM

Reich & Tang Deposit Networks, LLC (R&T) and Total Bank Solutions (TBS) Announce Plan to Combine Firms to Accelerate Growth, Drive Innovation and Expand Product Offerings

Retrieved on: 
Monday, March 28, 2022
AUA, Trust, Leadership, Investment, Growth, TBS, Entrepreneurship, Debevoise & Plimpton, Industry, Technology, Knowledge, Goal, DDM, Solution, DeBevoise, R, Insurance, FDIC, History, LMS, IDP, Management, Bank

Both firms have long track records of providing superior client service and developing innovative liquidity solutions.

Key Points: 
  • Both firms have long track records of providing superior client service and developing innovative liquidity solutions.
  • Both firms have long track records of providing superior client service and developing solutions that enhance their respective clients' experience and deliver value to their underlying customers.
  • "Similar to R&T, TBS is a well-established organization whose mission is focused on helping customers to achieve their goals.
  • Reich & Tang Deposit Solutions (R&T) offers deposit and liquidity solutions to financial intermediaries throughout the country.

SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies

Retrieved on: 
Thursday, February 24, 2022
U.S. Securities and Exchange Commission, Software as a service, Information, Algorithm, Twitter, Genome, Diagnosis, Sophia, Deep learning, Research, DDM, DNA sequencing, Laboratory, Drug development, Cancer, Molecular Cancer Research, LinkedIn, Multimedia, DNA, BRCA1, Sophia Genetics, HRR, BRCA2, Instagram, Forward-looking statement, GENETICS, Patient, Technology, PARP, Solution, CEO, HRD, Ovarian cancer, AstraZeneca, Medical imaging, Pharmaceutical industry, Medical device

BOSTON and LAUSANNE, Switzerland, Feb. 24, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples.

Key Points: 
  • SOPHiA GENETICS is collaborating with AstraZeneca, aiming to expand access to in-house HRD testing across European laboratories and institutions.
  • "We are pleased to work with SOPHiA GENETICS in their mission to empower their laboratory customers and increase the range of options available for HRD detection."
  • To combat current challenges with HRD detection offerings, the SOPHiA DDM HRD Solution provides laboratories and institutions with a decentralized approach to HRD testing for tumor samples.
  • SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise.

SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies

Retrieved on: 
Thursday, February 24, 2022
U.S. Securities and Exchange Commission, Software as a service, Information, Algorithm, Twitter, Genome, Diagnosis, Sophia, Deep learning, Research, DDM, DNA sequencing, Laboratory, Drug development, Cancer, Molecular Cancer Research, LinkedIn, DNA, BRCA1, Sophia Genetics, HRR, BRCA2, Instagram, Forward-looking statement, GENETICS, Patient, Technology, PARP, Solution, CEO, HRD, Ovarian cancer, AstraZeneca, Medical imaging, Pharmaceutical industry, Medical device

BOSTON and LAUSANNE, Switzerland, Feb. 24, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples.

Key Points: 
  • SOPHiA GENETICS is collaborating with AstraZeneca, aiming to expand access to in-house HRD testing across European laboratories and institutions.
  • "We are pleased to work with SOPHiA GENETICS in their mission to empower their laboratory customers and increase the range of options available for HRD detection."
  • To combat current challenges with HRD detection offerings, the SOPHiA DDM HRD Solution provides laboratories and institutions with a decentralized approach to HRD testing for tumor samples.
  • SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise.

SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8

Retrieved on: 
Monday, November 1, 2021
Research, Diagnosis, Technology, Huntingdon, Industry, Drug development, Workflow, DDM, NGS, Twitter, Software as a service, Patient, U.S. Securities and Exchange Commission, Agilent Technologies, Sophia, GENETICS, Forward-looking statement, Multimedia, Sophia Genetics, Solution, Medical device

BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today they have extended their SOPHiA DDM™ Universal Whole Exome analytical capabilities to include industry leading exome SureSelect Human All Exon v8 by Agilent. The new SOPHiA GENETICS pipeline is tailored to the unique features of this product to maximize support for Agilent customers in automating their next generation sequencing (NGS) workflows with enhanced, cutting-edge interpretation tools for germline and cancer applications.

Key Points: 
  • BOSTONandLAUSANNE,Switzerland, Nov. 1, 2021 /PRNewswire/ --SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine,announced today they have extended their SOPHiA DDM Universal Whole Exome analytical capabilities to include industry leading exome SureSelect Human All Exon v8 by Agilent.
  • SOPHiA GENETICS' Universal Whole Exome solution delivers a streamlined end-to-end workflow, from sample to variant report, to advance rare and inherited disease research studies using any exome product.The newSOPHiADDM for SureSelect Human All Exon v8 is a fully integrated, FASTQ-to-report bioinformatic workflow for whole exome analysis andinterpretation.
  • TheSOPHiADDM for SureSelect Human All Exon v8 offers:
    The SOPHiA DDM platform supports multiple commercially available exome panels with tailored pipelines and robust analytics for each, enabling uniform coverage of the target region and a streamlined workflow to reduce overall turnaround time and accelerate rare disease characterization.
  • To learn more about how SOPHiA GENETICS data-driven insights are improving diagnosis, treatment, and drug development for patients and the larger medical community, visit www.sophiagenetics.com .

SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8

Retrieved on: 
Monday, November 1, 2021
Research, Diagnosis, Technology, Huntingdon, Industry, Drug development, Workflow, DDM, NGS, Twitter, Software as a service, Patient, U.S. Securities and Exchange Commission, Agilent Technologies, Sophia, GENETICS, Forward-looking statement, Sophia Genetics, Solution, Medical device

BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today they have extended their SOPHiA DDM™ Universal Whole Exome analytical capabilities to include industry leading exome SureSelect Human All Exon v8 by Agilent. The new SOPHiA GENETICS pipeline is tailored to the unique features of this product to maximize support for Agilent customers in automating their next generation sequencing (NGS) workflows with enhanced, cutting-edge interpretation tools for germline and cancer applications.

Key Points: 
  • BOSTONandLAUSANNE,Switzerland, Nov. 1, 2021 /PRNewswire/ --SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine,announced today they have extended their SOPHiA DDM Universal Whole Exome analytical capabilities to include industry leading exome SureSelect Human All Exon v8 by Agilent.
  • SOPHiA GENETICS' Universal Whole Exome solution delivers a streamlined end-to-end workflow, from sample to variant report, to advance rare and inherited disease research studies using any exome product.The newSOPHiADDM for SureSelect Human All Exon v8 is a fully integrated, FASTQ-to-report bioinformatic workflow for whole exome analysis andinterpretation.
  • TheSOPHiADDM for SureSelect Human All Exon v8 offers:
    The SOPHiA DDM platform supports multiple commercially available exome panels with tailored pipelines and robust analytics for each, enabling uniform coverage of the target region and a streamlined workflow to reduce overall turnaround time and accelerate rare disease characterization.
  • To learn more about how SOPHiA GENETICS data-driven insights are improving diagnosis, treatment, and drug development for patients and the larger medical community, visit www.sophiagenetics.com .

Smiths News (SNWS) Initiation - Predictable cash flows and growing dividends

Retrieved on: 
Tuesday, October 19, 2021
DDM, Research, Smiths News, News, DCF, COVID-19

While the print sector is declining, revenue is predictable and management has a clearly demonstrable cost-saving track record such that cash flow is strong and profits are broadly flat, post COVID-19.

Key Points: 
  • While the print sector is declining, revenue is predictable and management has a clearly demonstrable cost-saving track record such that cash flow is strong and profits are broadly flat, post COVID-19.
  • This means that debt is being paid down and dividends are likely to become an increasing feature.
  • We value Smiths News at 77.4p/share based on a discounted cash flow (DCF) model, more than twice the current share price.
  • Given the predictable and consistent cash flow of the core business, we believe this is a reasonable methodology to adopt.

Markforged Releases Eiger™ Fleet to Scale Additive Manufacturing

Retrieved on: 
Monday, September 13, 2021
Software, Networks, Other Manufacturing, Hardware, Steel, Data Management, Technology, Manufacturing, Wind, Efficiency, Forward-looking statement, Adoption, Software, Carbon, Intention, CTO, Vestas, NYSE, Terminology, Industry, Automation, Solution, Blacksmith, 3D printing, DDM, Prospectus, RAPID, ERP, Society, Human, Organization, Proxy, SEC, Renewable energy

Today at RAPID + TCT 2021, Markforged , creator of the integrated metal and carbon fiber additive manufacturing platform, The Digital Forge, announced Eiger Fleet, a cloud-based software solution designed to accelerate the adoption of additive manufacturing operations at scale.

Key Points: 
  • Today at RAPID + TCT 2021, Markforged , creator of the integrated metal and carbon fiber additive manufacturing platform, The Digital Forge, announced Eiger Fleet, a cloud-based software solution designed to accelerate the adoption of additive manufacturing operations at scale.
  • Eiger Fleet helps to transform additive manufacturing from a small-scale operation to a large globally-connected, distributed manufacturing fleet by giving organizations a secure, cloud-connected and centralized source of control over their Markforged 3D printers, users and part production.
  • As the newest addition to the Markforged Eiger software portfolio, Eiger Fleet is designed to help manufacturers adopt disruptive additive manufacturing technologies into their more traditional workflows.
  • Eiger Fleet is setting the pace for whats possible in the future of manufacturing, through cloud-enabled distributed manufacturing.

Astonish Media Group Announces ddm marketing + communications Joins its Prestigious Portfolio of Clients

Retrieved on: 
Tuesday, August 31, 2021
Public relations, Television, LLC, Publishing, Founder, American Airlines, Growth, Human, GLOBE, DDM, ABC Television, Travel, Health, Marketing, Advertising, Automation, New, CEO, Education, Publication, Pernod Ricard, Media Group, Coca-Cola

New York, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Astonish Media Group , a leading boutique public relations and media strategy firm based in New York City, announces the addition of ddm marketing + communications to the agencys portfolio.

Key Points: 
  • New York, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Astonish Media Group , a leading boutique public relations and media strategy firm based in New York City, announces the addition of ddm marketing + communications to the agencys portfolio.
  • ddm marketing + communications is headquartered in Grand Rapids, Michigan and specializes in branding, communications, and digital marketing for highly complex and highly regulated industries.
  • Astonish Media Group has more than twenty years experience as a generalist and strategic media relations firm, with a wide range of clients including business, health, health-tech, non-profit, travel, lifestyle, food & beverage, and education.
  • We are honored to have ddm marketing + communications join the Astonish family as a leading communications, branding, and digital marketing agency, said Paula Conway, President and Founder of Astonish Media Group.

INNORULES to Enter the Southeast Asian Financial Market by Winning Digital Transformation Project of the Biggest Japanese Insurance Company

Retrieved on: 
Thursday, July 15, 2021
Professional services, Data management, Technology, Insurance, Finance, Software, Insurance, Premium, Types of insurance

INNORULES, a Korean professional developer of Business Rule Engine, supplied the Digital Product Manager to the innovative digital transformation project of one of the biggest insurance companies in Japan.

Key Points: 
  • INNORULES, a Korean professional developer of Business Rule Engine, supplied the Digital Product Manager to the innovative digital transformation project of one of the biggest insurance companies in Japan.
  • INNORULES is planning to expand into the South East Asian financial market upon this opportunity.
  • The Japanese company first met the INNORULES product when they visited Korea to benchmark Korean insurance companies and it eventually chose INNORULES after conducting the Benchmark Test.
  • The Japanese company adopted INNORULES Digital Product Manager (DPM) for their key tasks and simplified their merchandise structures such as insurance sales, insurance premium receipt, and premium settlement process.